Stocks › CVS
CVS HEALTH Corp
CVS·NYSE·
United States·USD
$80.84
+0.80 (+1.00%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CVS
CVS HEALTH Corp · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CVSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CVS by members of U.S. Congress · 384 on record · 22 in the last 12 months
Whale Activity
Position changes in CVS reported for 2026-09-30 by 2189 institutional filers
- Increased795
- New137
- Held250
- Decreased726
- Closed189
- No prior filing92
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 120.4M | $10.32B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 83.7M | $7.17B | increased |
| Capital World Investors | 74.0M | $6.35B | decreased |
| STATE STREET CORP | 60.1M | $5.15B | decreased |
| DODGE & COX | 46.0M | $3.95B | decreased |
| WELLINGTON MANAGEMENT GROUP LLP | 36.7M | $3.14B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 30.9M | $2.64B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 27.1M | $2.32B | increased |
| FMR LLC | 24.9M | $2.13B | decreased |
| BANK OF AMERICA CORP /DE/ | 23.6M | $2.02B | increased |
| JPMORGAN CHASE & CO | 22.1M | $1.93B | increased |
| Capital Research Global Investors | 21.9M | $1.87B | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CVS insiders, by quarter · Form 4
Recent Insider Transactions
1,893 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Shah Prem SEVP and Group President | Purchase | +23.9K | $83.89 | $2.0M | Nov 6, 2026 | Form 4 ↗ |
| Clark James DavidSVP, Cont & Chief Acct Officer | Tax withholding | −454 | $90.98 | $41K | Jun 26, 2026 | Form 4 ↗ |
| Newman BrianEVP, Chief Financial Officer | Tax withholding | −2,478 | $90.98 | $225K | May 31, 2026 | Form 4 ↗ |
| Compton-Phillips AmyEVP, Chief Medical Officer | Tax withholding | −7,618 | $90.98 | $693K | May 31, 2026 | Form 4 ↗ |
| AGUIRRE FERNANDODirector | Disposition to issuer | −1,563 | $93.50 | $146K | May 21, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −370.5K | $93.45 | $34.6M | May 21, 2026 | Form 4 ↗ |
| AGUIRRE FERNANDODirector | Disposition to issuer | −30.4K | $93.78 | $2.9M | May 20, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −800 | $96.28 | $77K | May 20, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −66.9K | $95.67 | $6.4M | May 20, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −152.7K | $94.81 | $14.5M | May 20, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −797.6K | $93.48 | $74.6M | May 20, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −151 | $95.18 | $14K | May 19, 2026 | Form 4 ↗ |
| ROBBINS LARRYDirector | Sale | −2.0M | $94.45 | $187.3M | May 19, 2026 | Form 4 ↗ |
| AGUIRRE FERNANDODirector | Grant / award | +1,563 | $97.15 | $152K | May 14, 2026 | Form 4 ↗ |
| Balser Jeffrey R.Director | Grant / award | +2,058 | $97.15 | $200K | May 14, 2026 | Form 4 ↗ |
| KIRBY J SCOTTDirector | Grant / award | +1,447 | $97.15 | $141K | May 14, 2026 | Form 4 ↗ |
| Norwalk Leslie VDirector | Grant / award | +1,447 | $97.15 | $141K | May 14, 2026 | Form 4 ↗ |
| SANSONE GUY PDirector | Grant / award | +1,447 | $97.15 | $141K | May 14, 2026 | Form 4 ↗ |
| BROWN C DAVID IIDirector | Grant / award | +1,544 | $97.15 | $150K | May 14, 2026 | Form 4 ↗ |
| Mandadi TilakEVP, Chief Exp & Tech Officer | Sale | −69.6K | $89.58 | $6.2M | May 8, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CVS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 40.5M | $4.19B | 0.18% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 33.1M | $3.42B | 0.20% | Jun 30, 2026 |
| Washington Mutual Investors Fund | 31.6M | $3.30B | 1.52% | Jul 31, 2026 |
| Dodge & Cox Stock Fund Dodge & Cox Funds | 31.7M | $3.28B | 2.77% | Jun 30, 2026 |
| Income Fund of America | 23.7M | $2.47B | 1.67% | Jul 31, 2026 |
| American Balanced Fund | 17.9M | $1.85B | 0.64% | Jun 30, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 17.6M | $1.82B | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 15.5M | $1.60B | 0.20% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 16.6M | $1.56B | 0.18% | Aug 31, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 12.1M | $1.26B | 0.49% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list CVS's shares (CUSIP 126650100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Dodge & CoxSCHEDULE 13G/A · passive (13G) · 50.0M shares3.9%
Aug 13, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming cvs health as client
- CVS HEALTH (AND SUBSIDIARIES)CVS HEALTH (AND SUBSIDIARIES) · 2026 Q3 · PHA, TAX, MMM, INS$2.0M
Filing ↗ - THEGROUP DC, LLCCVS HEALTH (AND SUBSIDIARIES) · 2026 Q3 · HCR, PHA$50K
Filing ↗ - MICHAEL BEST STRATEGIES LLCCVS HEALTH · 2026 Q3 · HCR, PHA, MMM, INS$110K
Filing ↗ - ALB SOLUTIONSCVS HEALTH (AND SUBSIDIARIES) · 2026 Q3 · HCR$70K
Filing ↗ - ALSTON & BIRD LLPCVS HEALTH · 2026 Q3 · HCR$30K
Filing ↗
Government Contracts
Federal awards to CVS HEALTH Corp · USAspending
No federal contract awards found for CVS HEALTH Corp.
U.S. Patents
Recent USPTO applications naming CVS HEALTH Corp
No USPTO patent applications found for CVS HEALTH Corp.
Annual Financials
From CVS's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B |
| Operating income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B |
| Diluted EPS | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 |
| Operating cash flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B |
| Cash and equivalents | $8.45B | $8.59B | $8.20B | $12.95B | $9.41B |
| Total assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.00B |
| Total liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $157.62B |
| Shareholders' equity | $75.21B | $75.56B | $76.46B | $71.47B | $75.08B |
As CVS HEALTH Corp tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 10, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitJun 7, 2005
- 2-for-1Stock splitJun 16, 1998
- 2-for-1Stock splitMar 15, 1989
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 9.01Reg FD disclosureNov 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureAug 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About CVS HEALTH Corp
From SEC EDGAR company records
Industry (SIC 5912)Retail-Drug Stores and Proprietary Stores
SectorConsumer
HeadquartersWOONSOCKET, RI
IncorporatedDE
SEC CIK0000064803 ↗
Former namesCVS CAREMARK CORP, CVS/CAREMARK CORP, CVS CORP









